ADHD

In a new study, patients with ADHD on cannabis-based medicinal products had significant improvements for anxiety, sleep quality, and health-related quality of life.

At the 14-year follow-up, ADHD medication use was associated with a 4% increased risk of cardiovascular diseases.

Adults with ADHD have greater reduction of symptoms with regulatory licensed doses of stimulants than unlicensed doses.

Two pivotal phrase 3 centanafadine trials show positive outcomes for children and adolescents with ADHD.

The rates of pediatric and adolescent treatment for depression, anxiety, ADHD, and behavior disorders vary by age, income level, and region.

Adult ADHD is associated with a 2.77-fold increased risk of dementia, according to new research.

Solriamfetol could potentially serve as a new ADHD treatment if future research goes positively.

Solriamfetol, typically used to treat narcolepsy and sleep apnea, has demonstrated it can reduce ADHD symptoms with no adverse cardiovascular effects.

These approvals of generics by the FDA can help to provide for patients with ADHD or BED the same clinical benefits as well as risks as the drugs’ brand-name counterparts.

The analysis of 500+ patients with ADHD shows no statistically significant evidence linking stimulant treatment to later substance use, indicating that stimulant medication did not increase or decrease the risk of substance use in adolescence or adulthood.

Participants who only initiated non-stimulant therapy for ADHD had significantly greater odds of past-year prescription stimulant misuse than the population controls.

The rate of sleep apnea is greater in patients with bipolar disorder and depression.

Treatment with benzodiazepines, antipsychotics, and antidepressants was associated with an increased risk of all-cause hospitalization or mortality, while mood stabilizer treatment did not have a statistically significant association with any of the predetermined outcomes and ADHD medications were linked to a lower risk of psychiatric hospitalization.

There was very little evidence of an effect growth or increased risk of psychiatric or neurological adverse events in the methylphenidate group compared with the no-methylphenidate group.

The potential mediating role of inflammation at 9 years, measured by CRP and IL-6, was investigated in the relationship between sleep and ADHD.

Parenting stress, negative parenting practices, broken parental partnership, critical life events, parental psychopathologies, socioeconomic status, and single-parent family were all significantly associated with ADHD symptom severity.

Some in the industry expect the Adderall shortage to possibly last until March 2023.

Drs Cerulli and Cutler discuss the data and pharmacological properties of amphetamine XR oral tablets.

Panelists discuss the use of amphetamine XR oral tablets in their practice and for which patients they’re using them.

They also found no statistically significant associations found for specific cardiovascular outcomes in relation to cardiac arrest or arrhythmias, cerebrovascular diseases, or myocardial infarction.

Data show an enhanced, auditory alert driving simulator may reduce distraction and inconsistent driving among teenagers with ADHD.

The strongest confounders were family income, caregiver education, and ADHD polygenic risk scores for ADHD clinical range diagnoses.

Birgit H. Amann, MD, PLLC, discusses 2 recently approved treatment options for ADHD: amphetamine XR oral tablets and viloxazine.

Panelists discuss the importance of choosing treatments that are individualized to their patients.

Psychiatrists share their approach to choosing between different ADHD medications and formulations.

Dr Feld highlights several formulations that are available to treat ADHD.

Dr Cutler shares treatment options for ADHD.

Dr Amann and other experts discuss importance of carefully weighing patient and parent expectations and goals when choosing treatment.

Drs Cerulli and Cutler discuss factors guiding treatment selection in ADHD.